Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E) (SIDEROS-E)
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study
Sponsor: Santhera Pharmaceuticals
Terminated
Interim analysis concluded to futility of main study SIDEROS (SNT-III-012)
Other terminated trials from Santhera Pharmaceuticals
Other Duchenne Muscular Dystrophy trials with similar outcome
This PHASE3 trial investigates Duchenne Muscular Dystrophy and is currently terminated or withdrawn. Santhera Pharmaceuticals leads this study, which shows 16 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2022 — Apr 2022 [monthly]
Terminated PHASE3
▶ Show 11 earlier versions
-
Jun 2021 — Jan 2022 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE3
-
May 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
First recorded
Jul 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Santhera Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .